UKRAINS'KYI VISNYK PSYKHONEVROLOHII

The Scientific and Practical Journal of Medicine
ISSN 2079-0325(p)
DOI 10.36927/2079-0325
Home » Archive of numbers » 2018 » Volume 26, issue 1 (94) » Reliable traditions and new opportunities: pharmacotherapeutic application features Zolafren. Message 1: Clinical pharmacology and phenomenology

Reliable traditions and new opportunities: pharmacotherapeutic application features Zolafren. Message 1: Clinical pharmacology and phenomenology

Authors

Type of Article

  • Scientific Article

In the Section

  • TO HELP A PRACTICING PHYSICIAN

Key words

Index UDK:
  • 616.89-008.441.1-07-08:615.214

Abstract

The article reviews and summarizes data on various aspects of the use of the new antipsychotics of the second generation of zolafren (olanzapine). The questions of infl uence of zolafrene on neurophysiological parameters (in particular, EEG) are considered. The issue of complex therapy of zolafren with selective serotonin reuptake inhibitors (SSRIs) and other drugs is discussed. These data can be used in the construction of treatment and rehabilitation programs for patients according to the algorithms described by us earlier.

Pages

  • 124-126

Year / Issue

Download PDF

References

  1. Yurieva, L. N. Schizophrenia: A Clinical Guide for Physicians. Dnipropetrovsk: New Ideology Publishing House, 2010. 244 p.
  2. Arana, J., Rosenbaum, D. Pharmacotherapy of Mental Disorders. Moscow: Binom, 2004. 416 p.
  3. Mosolov S. N. Fundamentals of Psychopharmacotherapy. Moscow, 1996. 288 p.
  4. Mosolov S. N. Current trends in the development of psychopharmacotherapy // Journal of Neuropathology and Psychiatry named after S. S. Korsakov. 1998. Vol. 98, issue 5. Pp. 12–19.
  5. Pharmacotherapy in Neurology and Psychiatry / edited by S. D. Enn, J. T. Coyle. Moscow: Medical Information Agency, 2007. 800 p.
  6. Olanzapine compared with other atypical antipsychotics in the treatment of schizophrenia / Komossa K., Rumel-Kluge K., Gunger H. [et al.] // Social and Clinical Psychiatry. 2012. Vol. 22, No. 1. Pp. 63–68.
  7. Standards for the treatment of patients with schizophrenia / edited by Krasnov V. N., Gurovich I. Ya., Mosolov S. N. [et al.] ; Moscow Research Institute of Psychiatry, Roszdrav. Moscow, 2006. Access mode: http://www.labclinpharm.ru/35.html ).
  8. Lyubov E. B. Pharmacological prognosis of maintenance therapy for patients with schizophrenia using Seroquel Prolong, risperidone (Risperdal), olanzapine (Zyprexa), and typical neuroleptics // Social and Clinical Psychiatry. 2012. No. 2. Pp. 66–74
  9. Mosolov S. N., Kalinin V. V., Sulimov Use of Zyprexa (olanzapine) in psychiatric practice: information letter / Moscow Research Institute of Psychiatry, Roszdrav. Moscow, 2002. Access mode: http://www.talagi.ru/library/ziprexa.htm
  10. Panko T. V. Dynamics of psychopathological and cognitive disorders in patients with schizophrenia during therapy // Ukrainian Journal of Psychoneurology. 2017. Vol. 25, issue 3 (92). Pp. 27–132.
  11. Mamchur A. I. Clinical and neurophysiological assessment of depressive disorders and optimization of treatment with antidepressants: abstract of dissertation ... candidate of medical sciences. Kiev, 1999. 19 p.
  12. Krasnov V. N. Affective spectrum disorders. М. : Izdvo "Practical Medicine", 2011: 432 p.
  13. Bipolar Disorder / Lakshmi N. Yatham, Gin S. Malhi. Oxford university press, 2011. 76 p.
  14. Bipolar Psychopharmacotherapy. Caring for the patient / edited by H. Akiskal and M. Tohen. 2nd ed. Wiley-Blackwell, 2011. 520 p.
  15. Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology / G. M. Goodwin, P. M. Haddad, I. N. Ferrier [et al.] // Journal of Psychopharmacology. 2016. Vol. 30 (6). P. 495—553.

Journal’s Indexing:

UKRAINS'KYI VISNYK PSYKHONEVROLOHII

The Scientific and Practical Journal of Medicine

ДУ «ІНПН імені
П.В. ВОЛОШИНА
НАМН УКРАЇНИ»